Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-18

Study Completion Date

2018-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the effectiveness of MR-HIFU for the treatment of uterine fibroids in Northwestern Ontario, which is a rural and remote setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound

NCT02633254

Uterine Fibroid

TERMINATED NA

Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids

NCT02386137

Uterine Fibroid

COMPLETED NA

Clinical Test of the MRgHIFU System on Uterine Fibroids

NCT02283502

Uterine Fibroids

UNKNOWN PHASE1

Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future

NCT00180739

Uterine Fibroids Pregnancy

WITHDRAWN PHASE4

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

NCT00995878

Symptomatic Uterine Leiomyomas Fibroids Uterine Fibroids +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Uterine fibroids are benign smooth muscle tumours of the muscular wall of the uterus that affect 40 per cent of women. While the majority of fibroids are asymptomatic, fibroids may cause menorrhagia, bulk symptoms (i.e. ureteric obstruction, urinary frequency and urgency, bowel dysfunction), pain and in certain instances infertility.

Magnetic resonance image-guided high-intensity focused ultrasound (MR-HIFU) treatment of fibroids is an established method for symptom alleviation with over 3000 women receiving treatment worldwide. MR-HIFU is a non-invasive, non-surgical procedure that uses ultrasound energy to thermally ablate the fibroid leading to a reduction in bleeding and in the size of uterine fibroids over time. MR-HIFU it is not currently being used for the treatment of symptomatic fibroids in Canada.

The Thunder Bay Regional Research Institute has one of the first clinically available MR-HIFU equipment in Canada. In order to bring this technology into clinical practice, a knowledge translation study is needed to demonstrate that MR-HIFU can treat symptomatic uterine fibroids as successfully in Northwestern Ontario compared to urban centres where all of the clinical trials have been conducted. The ability to screen and follow up women treated with MR-HIFU with ultrasound rather than MRI would allow participants to receive follow up in regional centres in Northwestern Ontario and it would be more cost effective from a health system perspective. In addition, more research is needed to broaden the scope of treatment to include fibroids greater than 8 cm such that more women could benefit from this non-surgical fibroid management option.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Leiomyoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fibroid dimension < 8 cm

Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.

Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound.

Group Type EXPERIMENTAL

Magnetic Resonance Guided High Intensity Focused Ultrasound

Intervention Type DEVICE

Direct treatment of uterine fibroids with MR-HIFU

Fibroid dimension > 8 cm

Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.

Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.

Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc.

Group Type EXPERIMENTAL

Magnetic Resonance Guided High Intensity Focused Ultrasound

Intervention Type DEVICE

Direct treatment of uterine fibroids with MR-HIFU

leuprolide acetate for depot suspension

Intervention Type DRUG

Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Guided High Intensity Focused Ultrasound

Direct treatment of uterine fibroids with MR-HIFU

Intervention Type DEVICE

leuprolide acetate for depot suspension

Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MR-HIFU Lupron Depot

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged 18 to 50 years
* Weight \<140kg
* Pre or perimenopausal
* Uterine size \<24 weeks
* Cervical screen by Pap test: Normal, Low Grade Squamous Intraepithelial Lesion, or Atypical Squamous Cells of Undetermined Significance as per Cancer Care Ontario guidelines
* Transformed symptom severity score ≥40
* Willing to attend all study visits
* Willing to complete evaluation forms
* Willing and able to use reliable contraception;

MR-HIFU Criteria Trial Arm 1:

* Minimum of 50% of fibroid volume accessible for treatment
* Dominant fibroid ≤8 cm
* Uterine volume \<900 cc
* Total fibroid treatment volume \<250 cc
* No more than 5 fibroids planned for ablation
* Completely non-enhancing fibroids should not be treated

MR-HIFU Criteria Trial Arm 2:

* Minimum of 50% of fibroid volume accessible for treatment
* Dominant fibroid \>8 cm or uterine volume \>900 cc
* Total fibroid treatment volume \<250 cc
* No more than 5 fibroids planned for ablation
* Completely non-enhancing fibroids should not be treated

Exclusion Criteria

* Other pelvic disease (endometriosis, ovarian tumor, acute pelvic disease, other mass)
* Significant systemic disease even if well controlled
* Positive pregnancy test
* Abnormal uterine bleeding (participant can be included if an endometrial biopsy confirms no hyperplasia or malignancy in the past 6 months)
* Extensive scarring along anterior abdominal wall (\>50% of area)
* Surgical clips or scar tissue in the path of the MR-HIFU beam
* MRI contraindicated according to standard operating procedure
* MRI contrast contraindicated (including renal insufficiency)
* Calcifications around or throughout uterine tissues
* Fibroids not quantifiable on MRI
* Highly perfused or brighter than myometrium in T2-weighted MRI fibroids (Type 3 fibroids).

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No